Market Overview

UPDATE: Bank Of America Reiterates On BioCryst Pharmaceuticals On Modestly Positive HAE Data

Share:

In a report published Wednesday, Bank of America analyst Steve Byrne reiterated an Underperform rating on BioCryst Pharmaceuticals (NASDAQ: BCRX), and raised the price target from $8.00 to $9.00.

In the report, Bank of America noted, “As we had expected, BCRX announced positive proof of concept data for its oral kallikrein inhibitor, ‘4161 in HAE prophylaxis. HAE attack rate/week was reduced by 35% (0.82 vs. pbo of 1.27, p<0.001), which fell short of Cinryze's 52% reduction in ph 3 (12 wk study) but we note differences in study design and duration (four weeks for BCRX). While compliance was 98% with four oral pills taken 3x/day, we believe the clinical trial setting and short four week duration allowed for higher compliance than likely seen in a real world setting.

"We raised our prob. of both US and ex-US approvals to 50% (from 35%), but lowered our peak WW patient estimates from 1750 to 1500 based on our view that ‘4161's efficacy is modest, could trend lower with lower compliance, and has significant patient-to-patient variability (below). These changes raised our PO to $9 (from $8). We continue to see potential for significant upside if one of BCRX' next generation one pill once/day candidates shows better bioavailability. BCRX plans to commence the OPuS-2 phase 2b trial later in 2014.”

BioCryst Pharmaceuticals closed on Tuesday at $9.99.

Latest Ratings for BCRX

DateFirmActionFromTo
Nov 2020Evercore ISI GroupInitiates Coverage OnOutperform
Jun 2020BTIGInitiates Coverage OnNeutral
May 2020BarclaysUpgradesEqual-WeightOverweight

View More Analyst Ratings for BCRX
View the Latest Analyst Ratings

 

Related Articles (BCRX)

View Comments and Join the Discussion!

Posted-In: Bank of America Steve ByrneAnalyst Color Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
STZUBSMaintains238.0
ZMRBC CapitalMaintains550.0
ZMStifelMaintains450.0
ZMJP MorganMaintains450.0
DISUBSMaintains155.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com